Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5201-5206

  Shah, Manish A ^a   Ramanathan, Ramesh K ^a   Ilson, David H ^a   Levnor, Alissa ^a   D'Adamo, David ^a   O'Reilly, Eileen ^a   Tse, Archie ^a   Trocola, Robin ^a   Schwartz, Lawrence ^a   Capanu, Marinela ^a   Schwartz, Gary K ^a   Kelsen, David P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APREPITANT; BEVACIZUMAB; CISPLATIN; DEXAMETHASONE; IRINOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH PERFORATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADENOCARCINOMA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECT; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846629672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.0887     Document Type: Article

References (30)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevelance across five continents: Defining priorities to reduce cancer disparities in different geographical regions of the world. J Clin Oncol 24:2137-2150, 2006
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
3. Blot WJ, DeVesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
4. Parfitt JR, Miladinovic Z, Driman DK: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada: An epidemiological study from 1964-2002. The Canadian J of Gastroent 20:271-276, 2006
5. Ajani JA, Baker J, Pisters P, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma. Cancer 94:641-646, 2002
6. Boku N, Ohtsu A, Shimada Y, et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323, 1999
7. Ilson D, Saltz L, Enzinger P, et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275, 1999
8. Pozzo C, Barone C, Szanto J, et al: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 15:1773-1781, 2004
9. Eroglu A, Demirci S, Ayyildiz A, et al: Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 80:1630-1634, 1999
10. Karayiannakis A, Syrigos KN, Polychronidis A, et al: Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg 236:37-42, 2002
11. Maeda K, Chung YS, Ogawa S, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863, 1996
12. Yoshikawa T, Tsuburaya A, Kobayashi O, et al: Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 153:7-12, 2000
13. Kanai T, Konno H, Tanaka T, et al: Anti-tumor and anti-metastatic effects of human vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77:185-190, 1998
14. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
15. Sandler AB, Gray R, Brahmer A, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 23:2s, 2005 (abstr 4)
16. Miller KD, Wang M, Gralow J, et al: E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. Breast Can Treat Res 35:51, 2005 (suppl 1; abstr 3)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. National Cancer Institute Common Toxicity criteria version 3. http://ctep.cancer.gov/reporting/ctc.html
19. Shah MA, Ilson D, Kelsen D: Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan and bevacizumab based therapy. J Clin Oncol 23:2574-2576, 2005
20. Shah MA, Schwartz GK: The treatment of metastatic esophagus and gastric cancer. Semin Oncol 4:574-587, 2004
21. Moiseyenko VM, Ajani JA, Tjuladin SA, et al: Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma. J Clin Oncol 23:308s, 2005 (abstr 4002)
22. Dank M, Zaluski J, Barone C, et al: Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st line advanced gastric cancer patients. J Clin Oncol 23:308s, 2005 (abstr 4003)
23. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004, 2002
24. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
25. Roviello F, Rossi S, Marrelli D, et al: Perforated gastric carcinoma: A report of 10 cases and review of the literature. World J Surg Onc 4:19, 2006.
26. Adachi Y, Mori M, Maehara Y, et al: Surgical results of perforated gastric carcinoma: An analysis of 155 Japanese patients. Am J Gastroent 92:516-518, 1997
27. Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil versus flourouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59, 2003
28. Ajani JA, Fodor MB, Tjulandin S, et al: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667, 2005
29. Sarela AI, Miner TJ, Karpeh MS, et al: Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243:189-195, 2006
30. Shah MA, Randazzo J, Saltz L, et al: High incidence of thromboembolic events in gastrointestinal malignancies, 2006. Gastrointestinal Cancers Symposium Program/Proceedings, San Francisco, CA, January 26-28, 2006, p 105 (abstr 41)